Sionnatx
Founded 2019 · 76 employees on LinkedIn · 3 known investors
Sionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs. It is advancing a portfolio of NBD1 stabilizers and complementary CFTR modulators intended to be used in combination to normalize CFTR function in CF patients.
Founders & leadership
Sionnatx was founded in 2019 by Greg and Mark.
G
GregCo-founder & Senior Vice President of Discovery Research
M
MarkCo-founder & Senior Vice President of Medicinal Chemistry
M
MikePresident & CEO
C
CharlotteChief Medical Officer
E
ElenaChief Financial Officer
C
CarolineChief Business Officer
J
JenChief Legal Officer
V
VanyaChief People Officer
Investors · 3
Frequently asked questions
- What does Sionnatx do?
- Sionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs. It is advancing a portfolio of NBD1 stabilizers and complementary CFTR modulators intended to be used in combination to normalize CFTR function in CF patients.
- Who founded Sionnatx?
- Sionnatx was founded by Greg, Mark in 2019.
- Who are Sionnatx's investors?
- Sionnatx's investors include Atlas Venture, OrbiMed, RA Capital.